Granted adequate target coverage, do you constrain dose to sub-volumes of the heart when treating locally advanced lung cancer?

This is a very important question that recent data is beginning to shed light on. It’s difficult to address cardiac sub-structures without first talking about mean heart dose, its evolution, and the relationship with baseline cardiac risk. While MHD certainly has its limitations, there is a utility ...